Protein metabolism in growth hormone deficiency, and effects of growth hormone replacement therapy.

The effects of growth hormone (GH) treatment on protein metabolism were studied in adults with GH deficiency (GHD). A double-blind, placebo-controlled trial of recombinant human GH, 0.018 IU/kg/day for 1 month followed by 0.036 IU/kg/day for 1 month, was performed with isotopic whole-body protein turnover studies at 0 and 2 months. In all, 18 adults with GHD (9 men, 9 women; mean age, 46.6 years; range, 30-56 years) were studied. Whole-body isotopic leucine turnover using L-[1-13C]leucine was assessed by measuring leucine Ra (a measure of protein degradation), non-oxidative leucine Rd (a measure of protein synthesis) and leucine oxidation rate. Lean body mass and circulating insulin-like growth factor I were significantly (p < 0.02) increased at 2 months in the GH-treated group, but not in the placebo group. There was no change in leucine Ra in either the placebo or GH-treated groups at 2 months. Leucine oxidation decreased (p < 0.01) and non-oxidative leucine Rd increased (p < 0.02) in the GH-treated group at 2 months. There was no significant change in either leucine oxidation or non-oxidative leucine Rd in the placebo group at 2 months. These results indicate that the increase in lean body mass resulting from GH treatment in adults with GHD is due to an increase in protein synthesis.